Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

104.41 +0.67 (+0.65%)
Streaming Delayed Price Updated: 3:25 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
94 95 Next >
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
This fund has a basket of growth, income, and value stocks. 
Via The Motley Fool
Topics ETFs
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Merck & Co Inc. DCF Valuation: Is The Stock Undervalued?
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. 
Via Talk Markets
Merck & Co's Options Frenzy: What You Need to Know
Via Benzinga
Evaluating Merck &amp; Co Against Peers In Pharmaceuticals Industry
Via Benzinga
Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
Merck secures legal victory as 3rd U.S. Circuit Court of Appeals upholds dismissal of 1,200 lawsuits over Zostavax shingles vaccine. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
2 Magnificent Stocks to Buy With $500
These reliable healthcare companies look attractive no matter how you slice it. 
Via The Motley Fool
3 Top Cancer Treatment Stocks to Buy Now
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill
3 Biotech Stocks to Buy in Case of Another Pandemic
These are three of the best biotech stocks to keep an eye on as the industry helps governments prepare for the next pandemic. 
Via InvestorPlace
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
From Merck & Co., Inc.
Via Business Wire
Merck's Acquisition of EyeBio Finalized
Merk announced the acquisition of EyeBio, introducing a novel candidate to the company's pipeline, Restoret. 
Via Benzinga
Forget Nvidia: Billionaires Are Dumping It and Piling Into These 3 Surprising Value Stocks Instead
Nvidia's three most-prominent billionaire sellers opted to put their respective fund's capital to work in a trio of brand-name companies trading at a discount. 
Via The Motley Fool
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer... 
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
Via Benzinga
Merck & Co Unusual Options Activity
Via Benzinga
Merck Completes Acquisition of EyeBio
From Merck & Co., Inc.
Via Business Wire
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Q2 estimates have been stable heading into earnings season, potentially setting a lower bar for corporations to beat analyst expectations and surprise to the upside. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
Merck Animal Health announced the purchase of Elanco Animal Health's aquaculture business.Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture bus 
Via Benzinga
3 Undervalued Blue-Chip Stocks Ready for a Big Comeback
Uncover top picks in undervalued blue-chip stocks, unfairly punished yet consistently delivering strong operational results 
Via InvestorPlace
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
94 95 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.